# Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis

> **NCT00646386** · PHASE2 · COMPLETED · sponsor: **Abbott** · enrollment: 315 (actual)

## Conditions studied

- Arthritis
- Psoriatic

## Interventions

- **DRUG:** adalimumab
- **DRUG:** placebo for adalimumab

## Key facts

- **NCT ID:** NCT00646386
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** 2004-04
- **Final completion:** —
- **Target enrollment:** 315 (ACTUAL)
- **Last updated:** 2008-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00646386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00646386, "Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00646386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*